---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-004097"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:27:49.637206+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma expects FY 2024 Portfolio Receipts ~$2.8B, at upper end of guidance

## Summary
- FY 2024 Portfolio Receipts expected ~$2,800M (upper end of $2,750-$2,800M range).
- Underlying Royalty Receipts growth ~13% YoY; Adjusted EBITDA ~$2,560-2,570M.
- Capital deployed $2.8B in 2024, record $925M synthetic royalty deals (Rytelo, Niktimvo, Yorvipath).
- Late-stage pipeline potential peak royalties >$1.2B/yr; key catalysts: pelacarsen (Phase 3 2025), aficamten (PDUFA Sept 2025).
- Announced acquisition of external manager and increased share repurchase commitment (details not provided in this release).

## SEC filing metadata
- accession: 0001193125-25-004097
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312525004097/0001193125-25-004097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312525004097/d921741d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-004097
- JSON: https://secwatch.observer/filing/0001193125-25-004097.json
- Plain text: https://secwatch.observer/filing/0001193125-25-004097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.